Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Solid Tumor 1Recurrence 1Leukemia, Myeloid, Acute 1Leukemia 1Clear-cell metastatic renal cell carcinoma 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × LY2510924 × Clear all
NCT01391130 2019-07-23

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Eli Lilly and Company

Phase 2 Terminated
110 enrolled 14 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Neoplasm Metastasis, Neoplasms

NCT01439568 2019-07-23

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

Eli Lilly and Company

Phase 2 Completed
90 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡